Skip to content
Screener

Integra LifeSciences IART Specialty Surgery — Total Costs & Expenses

Similar metrics at other companies

MML
MMLPSpecialty Products — Total Costs & Expenses
$2.47M-2.8%
Chevron logo
CVXSegment Total — Total Costs & Expenses
$51.78B+30.5%
PSK
PSKYStudios — Total Costs & Expenses
$1.12B
Journey Medical Corporation logo
DERMDermatological — Total Costs & Expenses
$18.19M+5.7%
DeFi Development Corp. logo
DFDVTreasury — Total Costs & Expenses
$56.78M
DocGo logo
DCGOCorporate — Total Costs & Expenses
$8.65M-27.1%

Other financials

Income statement

See full
Revenue$418.8M+0.8%
Gross profit$219.7M+5.0%
Operating income$19.3M+104%
Net income$4.5M+101%
EPS (diluted)$0.06+101%

Balance sheet

See full
Cash & equivalents$214.4M-1.6%
Total debt$2.0B+3.2%
Total equity$1.0B+0.5%
Total assets$3.6B-2.8%

Cash flow

See full
Operating cash flow$22.8M+156%
CapEx$12.3M-38.9%
Free cash flow$10.5M+193%

Valuation

See full
Market cap$1.33B+38.0%
Enterprise value$3.08B+16.2%
P/S0.8×+0.2×

Profitability

See full
Gross margin52.5%-0.1pp
Operating margin2.6%+1.3pp
Net margin-0.4%
FCF margin3.8%-6.3pp

Returns & leverage

See full
Return on equity-0.7%
Debt / equity1.9×+0.1×
Current ratio3.6×+2.4×

Where this comes from

Reported directly by Integra LifeSciences in its filing.

Tagged under the XBRL concept us-gaap:CostsAndExpenses.

The source filing: Integra LifeSciences’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 4:03 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000917520-26-000058
Dollars in thousandsThree Months Ended June 30, 2026 / Specialty SurgeryThree Months Ended June 30, 2026 / Tissue ReconstructionThree Months Ended June 30, 2026 / Corporate and OtherThree Months Ended June 30, 2026 / TotalSix Months Ended June 30, 2026 / Specialty SurgerySix Months Ended June 30, 2026 / Tissue ReconstructionSix Months Ended June 30, 2026 / Corporate and OtherSix Months Ended June 30, 2026 / Total
Research and development14,2008,1691,88424,25326,05315,7016,00047,754
Selling, general & administrative75,98340,39456,059172,436153,66483,920113,087350,671
Intangible asset amortization3,7703,7707,5467,546
Total cost and expenses220,39590,55288,529399,476420,404179,069180,451779,924
Operating income (loss)88,87418,940(88,529)19,285172,00039,206(180,451)30,755
Interest income4,2678,372
Interest expense(22,994)(45,459)
Other income, net4,1868,665

Item 1. Financial Statements

FAQ

What is Integra LifeSciences's specialty surgery — total costs & expenses?
Integra LifeSciences (IART) reported specialty surgery — total costs & expenses of $220.4M in Q2 2026.
What does specialty surgery — total costs & expenses mean?
This represents the aggregate of all operating costs, including cost of goods sold, R&D, and SG&A, incurred by the Specialty Surgery segment. It provides a comprehensive view of the total expenditure required to sustain the segment's operations and revenue generation.

Ask your AI about Integra LifeSciences's specialty surgery — total costs & expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude